bluuebunny/crossref_metadata_2025_split huggingface dataset:
MO072: PST3.1A, An Inhibitor of MGAT5 Decreases Renal Fibrosis in a Rat Model of Chronic Kidney Disease
Authors: Muyor Karen , Laget Jonas , Duranton Flore , Jover Bernard , Cortijo Irene , Loiseau Séverine , Chorro Karine , Jacquard Carine , Pau Bernard , Clarion Ludovic , Argiles Ciscart Angel , Gayrard Nathalie 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Renal fibrosis is a main feature of chronic kidney disease (CKD) that participates in its progression to the end stage.(1) N-acetylglucosaminyltransferase 5 (MGAT5) adds N-acetylglucosamines to newly synthesized glycoproteins and is overexpressed in tumors participating in epithelial–mesenchymal transition (EMT), invasion and cell migration, some of the features observed in fibrosis.(2) PST3.1a is an inhibitor of MGAT5 that has already been shown to be beneficial in the treatment of brain tumors.(3) We presently evaluated the use of PST3.1a on renal fibrosis in CKD.

METHOD
Six-week-old Sprague-Dawley rats underwent 5/6th subtotal nephrectomy (SNx) (n = 16) or no surgery (Control) (n = 14). PST3.1a (0.2 mg/mL) or placebo was administered in the drinking water from the day of surgery for the entire protocol. Animals were sacrificed 4 weeks after surgery and the kidney was taken to evaluate fibrosis, MGAT5 expression and activity. Fibrosis was determined both by Sirius red staining and by immunohistochemistry (IHC) staining of three types of collagen (I, III and IV). To measure the activity of MGAT5 immunohistochemistry staining of Phaseolus Vulgaris Leucoagglutinine (PHA-L) and galectin 3 were carried out.

RESULTS
MGAT5 expression (12.2% ± 1.2 control versus 26.7% ± 2.6 SNx) and renal fibrosis (11.5% ± 0.7 control versus 26.9% ± 1.9 SNx) increased significantly in SNx animals in a preliminary study.
In the present study, PST3.1atreatment significantly decreased the expression of collagen 1 (col1) (2.1% ± 0.2 SNx versus 1.3% ± 0.2 SNx + PST3.1a; P &lt; 0.05) and collagen 4 (col4) (9.4% ± 1.01 SNx versus 6.4% ± 0.3SNx + PST3.1a; P &lt; 0.05) in kidneys of SNx animals (Fig. 1). Collagen 3 also had a trend to decrease. Sirius red staining showed a decrease in the PST3.1a treated group although it did not reach statistical significance (8.4% ± 1.7SNx versus 6.7% ± 0.2 SNx + PST3.1a). PHA-L and galectin 3 expressions were increased in SNx animals, and the overexpression was blunted in PST3.1a treated animals (9.4% ± 1.5 SNx versus 5.7% ± 0.2 SNx + PST3.1a; P &lt; 0.05 for galectin 3) (Fig. 2).

CONCLUSION
Fibrosis was observed in SNx animals 4 weeks after surgery. PST3.1a significantly decreased MGAT5 activity. Treatment with PST3.1a decreased fibrosis and significantly downregulated col1 and col4. These data show that PST3.1a treatment through MGAT5 inhibition may be a new treatment for fibrosis in the context of CKD.
MO111: Hyperuricaemia and Risk of Simple Renal Cysts
Authors: Valentinova Monova Daniela , Kamenov Assen , Milenova Vladislava , Shumnalieva Russka , Monov Simeon 
Published: May 2022

Abstract

BACKGROUND AND AIMS
The relationship between hyperuricaemia and renal cysts is still insufficient. Simple renal cysts (SRCs) are the most common non-hereditary type of benign renal cysts in adults. The prevalence of SRC varies by population, geographic region and the imaging modality used. The overall prevalence of SRC is 4–12% in general populations. Most SRCs are asymptomatic, being accidentally detected by abdominal ultrasonography or computed tomography during a medical check-up. However, some cysts tend to increase in size and can be sufficiently large to cause pain, haematuria and/or urinary obstruction.
The aim of this study is to compare the risk of SRC in patients with and without hyperuricaemia.

METHOD
We retrospectively collected data on 246 non-smoking males (age 30–70 years) with SRC without hypertension, obesity and renal stones. In this study, patients with previous therapy with uric acid-lowering medication; patients with current acute complications of diabetes or urinary tract infections; and patients with cancer, blood disease, polycystic kidney disease, solitary kidney, urinary tract stenosis or kidney diseases were excluded. Albuminuria was defined as 24-h urine microalbuminuria of 30 mg and higher. SRCs were detected by ultrasonography. The sonographic criteria for the diagnosis of SRC included absent internal echoes, a smooth, sharply defined wall and posterior acoustic enhancement, indicating posterior through transmission that was not suspicious for a malignant renal mass. SPSS 22 for windows was used for analysing the study data. Chi-square and exact Fisher's tests were utilized, while continuous variables were assessed by Student's t-test. A P value of less than .05 was considered statistically significant.

RESULTS
SRC prevalence was significantly higher in hyperuricaemic (174 patients) than normouricemic subjects. Age (OR 1042, 95% CI 1032–1061, P &lt; .001) and albuminuria (OR 1189, 95% CI 1176–1892, P &lt; 05) are independent risk factors for SRC development. Patients with SRC and hyperuricaemia were more likely to be elderly males, and exhibited a longer duration of lower eGFR and higher serum uric acid, γ-glutamyl transferase, low-density lipoprotein cholesterol and plasma glucose level compared with those without SRC. The risk of SRC increased when the serum uric acid is more 460 μmol/L.

CONCLUSION
Of the 246 non-smoking males with SRC, 176 have hyperuricaemia. Patients who had a SRC were significantly older than patients without SRC (mean 58.27 versus 43.18 years), with lower glomerular filtration rate, more often suffer from coronary heart disease. Therefore, even asymptomatic hyperuricaemia requires standardized uric acid-lowering treatment to prevent the occurrence of SRC. According to our results, SRC patients should be careful to use uricosuric drugs.
MO171: Chronic Inflammation Might Protect Haemodialysis Patients from Severe COVID-19
Authors: Prietl Barbara , Odler Balazs , Kirsch Alexander H , Artinger Katharina , Eigner Manfred , Schmaldienst Sabine , Pfeifer Verena , Stanzer Stefanie , Eberl Anita , Raml Reingard , Rosenkranz Alexander , Brodmann Marianne , Eller Philipp , Pieber Thomas , Eller Kathrin 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Patients on haemodialysis (HD) are expected to have excess mortality in coronavirus disease 2019 (COVID-19). This was challenged by a recent study reporting HD patients to have comparable mortality and decreased ICU admissions when hospitalized with COVID-19. It was speculated that an altered immune system due to chronic inflammation might protect HD patients from severe COVID-19. Therefore, we designed a study to describe the peripheral blood immune phenotype in HD patients and respective controls with COVID-19.

METHOD
Sixty-four patients (31 HD, 33 non-HD) with PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and 16 control patients (10 HD, 6 non-HD) were prospectively included. According to symptoms, COVID-19 patients were categorized as asymptomatic/mild and moderate/severe COVID-19 phenotypes. Cytokine profiling and immune phenotyping were performed.

RESULTS
Th1 and Th17 plasma cytokine levels were highly increased in HD patients without SARS-CoV-2 infection and were not significantly regulated during COVID-19. In non-HD COVID-19 patients, these cytokines increased significantly with disease severity. While all patients with moderate/severe COVID-19 showed hallmarks of COVID-19 such as decreased CD3+ CD4+ and CD8+ and CD4+CD25hiFoxP3+ regulatory T cells, significantly increased CD38+CD8+ effector memory and CD38+CD8+ TEMRA T cells were detected in HD compared to non-HD patients with moderate/severe COVID-19. Furthermore, CD161+CD8+ T cells decreased significantly in non-HD COVID-19 patients dependent on disease severity, but not in HD patients. Dynamics of B cells and subtypes were comparable in HD and non-HD COVID-19 patients. Significantly fewer moderate/severe COVID-19 HD patients needed ICU treatment [1/13 (7.7%) HD, 12/24 (50%) non-HD], whereas no difference in mortality was observed [4/31 (12.9%) HD, 6/33 non-HD (18.2%)].

CONCLUSION
HD patients might be protected from severe COVID-19 due to their chronic inflammatory state with increased CD38+CD8+ effector memory and TEMRA T cells as well as CD161+CD8+ T cells.
MO176: Study of Urinary Monocyte Chemoattractant Protein-1(MCP-1) Level in Morbidly Obese Patients before and After Bariatric Surgeries and its Relation to Renal Function
Authors: Sabry Alaa , Eldeep Ahmed 
Published: May 2022

Abstract

BACKGROUND AND AIMS
To assess the level of renal inflammatory marker monocyte chemoattractant protein -1(MCP-1), measure the urinary MCP to urinary creatinine concentration ratio in morbidly obese patients before and after bariatric surgeries. To study if there any possible relation between the MCP1 levels and renal function before and after surgery.

METHOD
This prospective study of 40 morbidly obese patients undergoing bariatric surgery was recruited in the study in the interval between October 2018 and July 2019. Evaluate the level of MCP-1, urinary creatinine, urinary albumin, glomerular filtration rate, body weight, body mass index, CRP, serum albumin, blood pressure and lipid profile before and after 3 months of bariatric surgeries.

RESULTS
The mean urinary level of MCP1 preoperative was 105.19 ± 15.25 pg/mL (range between 75.41 and 131.67) and this level was decreased postoperatively to 74.20 ± 22.77 (range between 30.5 and 114.4) with high statistically significant difference (P &lt; .001). While urinary MCP1/creatinine ratio, bariatric surgery significantly reduced the mean of urinary MCP1/creatinine ratios from 2.08 ± 1.43 to 0.86 ± 0.51 (P &lt; 0.001). Significant improvement of blood pressure, CRP, lipid profile and body mass index after bariatric surgeries.

CONCLUSION
We reported that urinary MCP-1 levels following bariatric surgery can be used as potential marker to the ongoing renal inflammatory process.
MO182: Safety Analysis of Anticoagulant Therapy in Stage 4 CKD in Combination with AF
Authors: Igamberdieva Ranokhon , Abdullaev Sherzod 
Published: May 2022

Abstract

BACKGROUND AND AIMS
A renocardial comorbid condition with a combination of chronic kidney disease (CKD) and atrial fibrillation (AF) increases the risk of thromboembolic complications (TEC) and hemorrhagic events. As kidney function worsens, this risk only increases. Anticoagulant therapy is the standard for prevention of acute cerebrovascular accident (ACVA) in AF. Clinical data on the use of new oral anticoagulants (NOACs) in patients with advanced CKD and AF are very limited, which indicates the relevance of research. Analysis of safety and efficacy indicators of rivaroxaban in patients with stage 4 CKD in combination with AF.

METHOD
The study included 106 patients with a glomerular filtration rate (GFR) of 15–29 mL/min/1.73 m2 and AF. A total of 73 patients took rivaroxaban at a dose of 15 mg/day and 33 patients took warfarin, the dose of which was individually adjusted according to INR values. The average follow-up period was 18 months. Thromboembolic complications were the primary endpoint. The secondary endpoint is the development of haemorrhagic events (major and minor bleeding).

RESULTS
In the rivaroxaban group, the mean CHA2DS2 VASc score was 4.9, the HAS BLED score was 3.2, and in the warfarin group, 4.5 and 3.1, respectively. The incidence of stroke in the rivaroxaban group was observed in one patient (1.37%), and in the warfarin group in two patients (6.06%). The results of the study on the primary endpoint indicate that the indicators in both groups did not differ significantly (P = .24). The incidence of haemorrhagic events such as minor bleeding in the rivaroxaban group on the BARC scale was n = 31 (42.5%), and n = 24 (72.7%) in the warfarin group (P &lt; .01). This indicator on the ISTH scale is n = 27 (36.9%) and n = 21 (63.6%), respectively. Major bleeding was observed in the rivaroxaban group n = 2 (2.74%), and in the warfarin group n = 2 (6.06%) on the BARC and ISTH scales (P = .31). Heamorrhagic events were significantly more frequent in the warfarin group compared with the rivaroxaban group.

CONCLUSION
The data obtained from this study indicate a favourable safety profile of NOAC (rivaroxaban) compared with a vitamin K antagonist in patients with stage 4 CKD in combination with AF.
MO185: Post-Translational Carbamylation of Sortilin is Associated with Cardiovascular Calcification in Chronic Kidney Disease
Authors: Jankowski Vera , Saritas Turgay , Kjobly Mads , Speer Thimoteus , Thirup Soren , Kramann Rafael , Jankowski Joachim , Floege Jürgen , Marx Nikolaus , Göttsch Claudia 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Sortilin, an intracellular sorting receptor, has been identified as a cardiovascular (CV) risk factor in the general population. Patients with chronic kidney disease (CKD) are highly susceptible to developing CV complications such as CV calcification. However, specific CKD-induced post-translational protein modifications of sortilin and their link to CV calcification remain unknown.

METHODS
Circulating sortilin isolated from two independent CKD cohorts was analysed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF/TOF mass spectrometry). The binding partner affinity was analysed by surface plasmon resonance spectroscopy. The effect of carbamylated sortilin on vascular calcification was analysed in vitro using human coronary artery smooth muscle cells.

RESULTS
In CKD patients, targeted mass spectrometric analyses of circulating sortilin revealed an increase in carbamylated lysine residues with kidney function decline. Carbamylation did not affect dimer formation of sortilin assessed by mass spectrometry. We observed an increased affinity of interleukin 6 to in vitro carbamylated sortilin. Carbamylated sortilin increased SMC calcification in vitro that was accelerated by interleukin 6, while carbamylated albumin and collagen type I did not affect SMC calcification. Mass-spectrometry imaging of human calcified arteries revealed in situ carbamylated sortilin. In CKD patients, sortilin carbamylation was associated with coronary artery calcification volume, independent of age, kidney function and other risk factors. Moreover, patients with carbamylated sortilin displayed significantly faster coronary artery calcification progression than patients without sortilin carbamylation.

CONCLUSION
Carbamylated sortilin is a risk factor for CV calcification and may contribute to elevated CV complications in patients with CKD.
MO193: Capillary Point-Of-Care Creatinine Testing in Kidney Disease Patients
Authors: Rosset-Zufferey Sarah , Emanuel Uehlinger Dominik , Sidler Daniel 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Creatinine measurement is part of daily nephrological practice to estimate the glomerular filtration rate (eGFR). Creatinine is usually measured in plasma or in serum by the Jaffe method or enzymatic reactions [1]. New point-of-care testing (POCT) devices have been developed to allow rapid creatinine quantification from venous, arterial or capillary samples [2, 3]. Importantly, capillary sampling and quantification could enable autonomous patient-performed creatinine measurements at home. This method has so far not been extensively tested in chronic kidney disease (CKD), kidney transplanted (TPL) and haemodialysis [HD]-dependent patients. The 2-fold aim of this study was to assess the adequacy and patient acceptance of capillary creatinine POCT in the aforementioned different kidney disease patients’ groups.

METHOD
Consecutive eligible patients followed at the nephrology outpatient unit of the Bern University Hospital were included. In each patient, creatinine was both measured by Nova Max® Creatinine in three different capillary measurements (index test) and from venous sampling by the central hospital laboratory (enzymatic reference test). In HD patients, analyses were performed before and after a HD session. Intra-essay variation and correlation between the index and the reference test were calculated. In order to explore patients’ acceptance and perception of autonomous capillary creatinine measurement at home, subjects were asked to fill a standardized survey.

RESULTS
A total of 128 patients were included: 33 CKD, 68 TPM and 27 HD. Capillary POCT creatinine ranged from 55–604 umol/L, 50–458 umol/L and 133–872 umol/L for CKD, TPL and HD patients, respectively. Intra-assay variation was 23 umol/L (IQR: 10.5–47.5 umol/L), corresponding to 12% (IQR: 7–21%) variation. Correlation between capillary and plasma creatinine was high at r2 = 0.89, 0.76 and 0.72 for CKD, TPL and HD patients, respectively. Within the latter group, correlation was considerably higher after dialysis (r2 = 0.83) compared to before dialysis (r2 = 0.55). Overall, 54 patients (42%) filled the questionnaire; 97% considered POCT creatinine an easy test to perform and 94% considered it an implementable test at home. Over three quarters of the sample (77%) associated such intervention with improvement for patient care. Patients were particularly sensitive to the potential time saving and capacity to monitor their creatinine levels swiftly.

CONCLUSION
Autonomous capillary POCT creatinine measurement is an adequate, relevant and implementable test in specific subgroups of kidney disease patients. Correlation with plasma creatinine is high for CKD and TPL patients, while there are important inter-assay variations in HD patients. This test has economical, ecological and logistic implications that warrant further evaluation. The next step in evaluating this test would require an investigation of its reproducibility and clinical impact over time.
MO196: Moderate-To-Severe CKD-Associated Pruritus (CKD-AP) is Independently Associated with Worse Health-Related Quality of Life (HRQOL) Among Dialysis Patients
Authors: Ion Titapiccolo Jasmine , Bellocchio Francesco , Goethel-Paal Berit , Eva Baró Salvador Maria , Schofield Michaela , Rincon Bello Abraham , Chrisholm Chis , Basnayake Kolitha , Trkulja Marjelka , Stuard Stefano , Neri Luca 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Chronic kidney disease–associated pruritus (CKD-aP) is common, yet underrecognized condition among end-stage kidney disease patients. We sought to evaluate the prevalence of CKD-aP and its impact on health-related quality of life (HRQOL) among dialysis patients across five European countries.

METHOD
This is a retrospective, observational analysis of data abstracted from the EuCliD® database (European Clinical database), the clinical information system adopted in Fresenius Medical Care (FMC) outpatient dialysis facilities in several European countries. Patient-Reported Outcomes Measures (PROM) were collected as part of a continuous quality improvement program launched for the first time in all centres belonging to the Nephrocare network in France, Italy, Spain, United Kingdom and Ireland. The presence and severity of CKD-aP were documented based on information captured by both the Kidney Disease Quality of Life (KDQOL™-36) and the 5-D Itch questionnaires. HRQOL was assessed with KDQOL™-36. Clinical and demographic data have been extracted from EuCliD®. The relationship between CKD-aP and HRQOL was evaluated with generalized linear models.

RESULTS
The ePROM campaign attained a large participation rate with very low attrition. Among 9974 who were actively treated in the clinics and were able to fill in a self-reported questionnaire, 8157 responded to the survey and only 1033 (11.2%) refused to participate. We enrolled 6221 patients in the present secondary analysis. The study flowchart is reported in Figure 1. Slightly more than half of patients (52%) reported no CKD-aP, 25% mild, whereas roughly 23% reported moderate-to-severe CKD-aP. Patients reporting more severe CKD-aP had shorter dialysis vintage, higher phosphate and parathormone, and more frequently diabetes. Average KDQOL-36 scores are reported in Figure 2a. We observed a strong, graded relationship between CKD-aP severity and KDQOL-36 scores (Figure 2b). The association was robust to adjustment for potential confounders. The quality of life penalty associated with more severe pruritus was clinically significant based on distribution based minimal clinically important difference threshold for the KDQOL-36 scales.

CONCLUSION
CKD-aP was common in a large, representative sample of the dialysis population in five European countries. We observed a large, clinically important, quality of life penalty associated with CKD-aP even after adjusting for potential confounders.
MO201: Effects of Aspirin in Primary Prevention of Cardiovascular (CV) Disease in People with Chronic Kidney Disease (CKD): Results of the TIPS3 Trial
Authors: Mann Johannes F E , Joseph Philip , Gao Peggy , Pais Prem , Xavier Denis , Dans Tony , Lopez Jaramillo Patricio , Gamra Habib , Tyrwhitt Jessica , Yusuf Salim 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Subjects with CKD carry a high (CV) risk. Whether this risk is blunted by aspirin is controversial. We examined CV outcomes of CKD participants of the TIPS3 trial.

METHOD
The International Polycap Study3 (TIPS3) randomized people (N = 5713) with and without CKD, but without previous CV disease, to aspirin, aspirin plus polypill, polypill or respective placebo in a factorial design. In 983 participants that were randomized to aspirin or placebo, eGFR was below 60 mL/min/1.73 m2 at baseline (CKD). The primary outcome for this comparison was non-fatal myocardial infarction (MI), non-fatal stroke or CV death. The mean follow-up was 4.6 years.

RESULTS
In all participants, there were 250 primary MACE outcomes, 116 on aspirin and 134 on placebo (HR 0.86; 95% CI 0.67–1.10). In those with CKD, there were 65 primary MACE outcomes, 26 in the 502 participants on aspirin, 39 in the 481 participants on placebo, HR 0.57 (95% CI 0.34–0.94). Directionally similar results were found for aspirin versus placebo for the secondary outcome all-cause death with 312 events in all participants (HR 0.87; 0.70–1.07) and 82 events in CKD patients (HR 0.64; 0.41–0.99). There was no significant interaction of eGFR &lt;60 mL/min with the treatment effects of aspirin versus placebo. Major and minor bleedings were rare and not different between groups.
When aspirin was combined with a polypill (containing atenolol, ramipril, hydrochlorothiazide and simvastatin) and compared to double placebo, in all participants the HR for the MACE outcome was 0.69, 0.50–0.97 and for all-cause death 0.80, 0.59–1.08; in CKD patients the HR was 0.37, 0.18–0.75 for MACE and HR 0.49, 0.29–0.97 for death.

CONCLUSION
Results suggest that the CV risk in people with CKD may be substantially alleviated with aspirin alone and in combination with a polypill.